AC Immune Ownership

ACIU Stock

USD 2.73 0.02 0.74%

AC Immune secures a total of 98.94 Million outstanding shares. AC Immune shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.

Shares in Circulation

First Issued

2016-03-31

Previous Quarter

100 M

Current Value

101 M

Avarage Shares Outstanding

72.9 M

Quarterly Volatility

13.9 M

Yuan Drop

Covid

Some institutional investors establish a significant position in stocks such as AC Immune in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of AC Immune, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Dividends Paid is likely to gain to 8,452 in 2024, despite the fact that Dividend Paid And Capex Coverage Ratio is likely to grow to (71.64). Common Stock Shares Outstanding is likely to drop to about 73.3 M in 2024. Net Loss is likely to gain to about (60.5 M) in 2024.

Market Cap Enterprise Value

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

ACIU Stock Ownership Analysis

About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. AC Immune recorded a loss per share of 0.44. The entity had not issued any dividends in recent years. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. AC Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on AC Immune please contact Andrea Pfeifer at 41 21 345 91 21 or go to https://www.acimmune.com.

Besides selling stocks to institutional investors, AC Immune also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AC Immune's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AC Immune's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

AC Immune Quarterly Liabilities And Stockholders Equity

244.25 Million

About 22.0% of AC Immune are currently held by insiders. Unlike AC Immune's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AC Immune's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AC Immune's insider trades

ACIU Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as AC Immune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AC Immune backward and forwards among themselves. AC Immune's institutional investor refers to the entity that pools money to purchase AC Immune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Eversept Partners, Llc	2024-09-30	99.3 K
Alps Advisors Inc	2024-09-30	76.6 K
Morgan Stanley - Brokerage Accounts	2024-09-30	64.9 K
Geode Capital Management, Llc	2024-09-30	58.3 K
Two Sigma Investments Llc	2024-09-30	57.3 K
Dimensional Fund Advisors, Inc.	2024-09-30	57.1 K
Man Group Plc	2024-09-30	27.4 K
Group One Trading, Lp	2024-09-30	24.1 K
Citadel Advisors Llc	2024-09-30	21.8 K
Bvf Inc	2024-09-30	19.5 M
Blackrock Inc	2024-06-30	2.6 M

Note, although AC Immune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

AC Immune Outstanding Bonds

AC Immune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AC Immune uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ACIU bonds can be classified according to their maturity, which is the date when AC Immune has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	Volcan Compania Minera Corp Bond USP98047AC08	View
	Boeing Co 2196 Corp Bond US097023DG73	View
	MPLX LP 4875 Corp Bond US55336VAG59	View
	MPLX LP 4125 Corp Bond US55336VAK61	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	Morgan Stanley 3971 Corp Bond US61744YAL20	View

View All AC Immune Corporate Bonds

AC Immune Corporate Filings

6K	18th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
13A	13th of December 2024 An amended filing to the original Schedule 13G	View Verify
	26th of July 2024 Other Reports	View Verify
	14th of March 2024 Other Reports	View Verify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC